Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Anavex Life Sciences Corp.NASDAQ: AVXL
Stock-Based Compensation · Q1 FY2026 · quarter ended Dec 2025
Stock-based compensation dips below year-ago levels
Q1 FY2026 stock-based compensation of $1.11M fell 46.1% year over year, behind the +15.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 70.2% from the prior quarter. Over 3 fiscal years it compounded at -14.3% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -46.1% toward the trailing-twelve-month pace of +15.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 11.55M USD
- Year-over-year change
- +22.4%
- 4-year CAGR
- +8.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 11.55M | +22.4% |
| FY2024 | 2024-09-30 | 9.44M | -42.3% |
| FY2023 | 2023-09-30 | 16.37M | -10.9% |
| FY2022 | 2022-09-30 | 18.38M | +123.3% |
| FY2021 | 2021-09-30 | 8.23M | — |
Stock-Based Compensation vs competitors
How AVXL compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.1% is the 6th highest of 9, against a peer median of +29.2%.
- Over three fiscal years its annual growth of -14.3% compares with a peer median of +1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.93M USD | +107.3% | -8.3% | 60.1% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $41.75M USD | +456.0% | +204.9% | — |
| LTM Sep 2026 | $35.82M USD | +41.1% | +7.4% | — | |
| LTM Mar 2026 | $34.64M USD | -7.4% | -5.4% | 39.4% | |
| LTM Mar 2026 | $23.96M USD | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $18.8M USD | -77.8% | -16.5% | 21.0% | |
| LTM Mar 2026 | $13.53M USD | -11.4% | +13.5% | 737.0% | |
| LTM Dec 2025 | $10.6M USD | +15.1% | -14.3% | — | |
| LTM Mar 2026 | $9.12M USD | +17.3% | -21.7% | 25.6% | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding AVXL) | — | +29.2% | +1.0% | 32.5% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.23M | 18.38M | 16.37M | 9.44M | 11.55M |
| Change in Working Capital | (706K) | 5.36M | 2.51M | 2.75M | (4.22M) |
| Accounts Receivables | (4.29M) | 5.94M | 484K | 260K | 1.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 751K | (914K) | 497K | 5.31M | (5.38M) |
| Other Working Capital | 2.83M | 331K | 1.52M | (2.81M) | (478K) |
| Other Non-Cash Items | 0 | 0 | 845K | 0 | 0 |
| Operating Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 153.22M | 22M | 29.65M | 11.98M | 12.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24K | (707K) | 29.65M | 11.98M | (2.71M) |
| Financing Cash Flow | 153.24M | 21.29M | 29.65M | 11.98M | 9.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 122.86M | (2.95M) | 1.87M | (18.84M) | (29.61M) |
| Free Cash Flow | (30.38M) | (24.24M) | (27.79M) | (30.81M) | (39.04M) |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.